Novozymes and Chr. Hansen Complete Merger, Forming Novonesis

In a significant development in the biosolutions sector, Novozymes A/S and Chr. Hansen Holding A/S successfully completed their merger, forming a new entity named Novonesis. This move, initially announced on December 12, 2022, has increased the share capital to DKK 936,597,292 through new B-shares. Novonesis is expected to show robust financial growth, with projected organic revenue growth of 6-8% through 2025 and an estimated annual revenue of € 3.7 bn.

The company aims to lead in innovating solutions for a healthier living, better food, reduced chemical use, and climate-neutral practices. “Novonesis combines our joint strengths and the wonders of biology, and we are set to lead a new era of biosolutions. We will innovate and develop transformative biosolutions that improve the way we all produce, consume and live,” said Novonesis CEO Ester Baiget. Its ESG goals include carbon neutrality by 2050 and a balanced gender representation in senior management by 2030. The company has outlined its financial reporting structure and will report in EUR. Key future events include a Capital Markets Day on June 18, 2024, and the final merger settlement on February 1, 2024.